Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 9, 22 | -0.59 | -0.59 |
Aug 11, 22 | -0.53 | -0.46
Decreased by
-15.22%
|
May 10, 22 | -2.98 | -0.52
Decreased by
-473.08%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-11.34 M
Decreased by
-126.46%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-10.12 M
Decreased by
-394.14%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00 - | -7.66 M - |
Decreased by
N/A%
-
|
Sep 30, 21 | 0.00 - | -6.94 M - |
Decreased by
N/A%
-
|
Jun 30, 21 | 0.00 - | -5.01 M - |
Decreased by
N/A%
-
|
Mar 31, 21 | 0.00 - | -2.05 M - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.